BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed BMY catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:57d40ed0c51e2131b826@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:BMY P2 readout (est.): AURORA-HFpEF
DESCRIPTION:Study to Evaluate Safety\, Tolerability and Drug Levels of BMS-
 986435/MYK-224 in Participants With Heart Failure With Preserved Ejection 
 Fraction (HFpEF)\nNCT06122779 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: 
 Bristol-Myers Squibb\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nTicker BMY (confidence 0.9)\nSource: https://cli
 nicaltrials.gov/study/NCT06122779\nScheduling/reference data from public r
 ecords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06122779
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ba09db051ad8f667387c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:BMY P2 readout (est.): TargetTau-1
DESCRIPTION:Study to Evaluate the Efficacy\, Safety\, and Tolerability of a
 n Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Earl
 y Alzheimer's Disease\nNCT06268886 | PHASE2 | ACTIVE_NOT_RECRUITING | spon
 sor: Bristol-Myers Squibb\nPrimary completion date (ESTIMATED)\; top-line 
 results usually follow later.\nTicker BMY (confidence 0.9)\nSource: https:
 //clinicaltrials.gov/study/NCT06268886\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06268886
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e9e8c1d4c61bb37d1b62@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:BMY P1/P2 readout (est.): A Study to Evaluate BMS-986470 in Healthy
  Volunteers and Participants With Sickle Cell Disease
DESCRIPTION:A Study to Evaluate BMS-986470 in Healthy Volunteers and Partic
 ipants With Sickle Cell Disease\nNCT06481306 | PHASE1/PHASE2 | RECRUITING 
 | sponsor: Bristol-Myers Squibb\nPrimary completion date (ESTIMATED)\; top
 -line results usually follow later.\nTicker BMY (confidence 0.9)\nSource: 
 https://clinicaltrials.gov/study/NCT06481306\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06481306
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:4b9ed9ca01ccf046e8f6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:BMY P2 readout (est.): CheckMate-1533
DESCRIPTION:A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolum
 ab in Combination With Intravenous Ipilimumab and Chemotherapy in Particip
 ants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung
  Cancer (NSCLC)\nNCT06946797 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: B
 ristol-Myers Squibb\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nTicker BMY (confidence 0.9)\nSource: https://clin
 icaltrials.gov/study/NCT06946797\nScheduling/reference data from public re
 cords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06946797
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2bb3b5e18b1cded517a6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270216
DTEND;VALUE=DATE:20270217
SUMMARY:BMY P3 readout (est.): A Study of Repotrectinib Versus Crizotinib i
 n Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibit
 or (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-
 3)
DESCRIPTION:A Study of Repotrectinib Versus Crizotinib in Participants With
  Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS
 1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)\nNCT06140836 | P
 HASE3 | ACTIVE_NOT_RECRUITING | sponsor: Bristol-Myers Squibb\nPrimary com
 pletion date (ESTIMATED)\; top-line results usually follow later.\nTicker 
 BMY (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06140836
 \nScheduling/reference data from public records\; dates can move. Not inve
 stment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06140836
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b92d1ef30d876c4e25f1@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260930
DTEND;VALUE=DATE:20261001
SUMMARY:BMY APPROVAL: CAMZYOS
DESCRIPTION:Approved 2026-09-30: CAMZYOS (NDA214998 SUPPL13)\nConfidence: c
 onfirmed\nTicker BMY (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214998\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=214998
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:8dd69212e162aac7a9a6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260813
DTEND;VALUE=DATE:20260814
SUMMARY:BMY APPROVAL: ZENBEXUS
DESCRIPTION:Approved 2026-08-13: ZENBEXUS (NDA221075 ORIG1)\nConfidence: co
 nfirmed\nTicker BMY (confidence 0.9)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=221075\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221075
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:6dc3bc7444ce04c12db8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260409
DTEND;VALUE=DATE:20260410
SUMMARY:BMY APPROVAL: ONUREG
DESCRIPTION:Approved 2026-04-09: ONUREG (NDA214120 SUPPL3)\nConfidence: con
 firmed\nTicker BMY (confidence 0.6)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214120\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=214120
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:eb2c953f9ea000408c78@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260320
DTEND;VALUE=DATE:20260321
SUMMARY:BMY APPROVAL: OPDIVO
DESCRIPTION:Approved 2026-03-20: OPDIVO (BLA125554 SUPPL135)\nConfidence: c
 onfirmed\nTicker BMY (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=125554
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:03b10e1640b6971fc8de@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260306
DTEND;VALUE=DATE:20260307
SUMMARY:BMY APPROVAL: SOTYKTU
DESCRIPTION:Approved 2026-03-06: SOTYKTU (NDA214958 SUPPL2)\nConfidence: co
 nfirmed\nTicker BMY (confidence 0.6)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214958\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=214958
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:21c3c26e579fbce445fb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251124
DTEND;VALUE=DATE:20251125
SUMMARY:BMY APPROVAL: OPDIVO QVANTIG
DESCRIPTION:Approved 2025-11-24: OPDIVO QVANTIG (BLA761381 SUPPL5)\nConfide
 nce: confirmed\nTicker BMY (confidence 0.9)\nSource: https://www.accessdat
 a.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761381\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761381
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
